CHINARES PHARMA (03320) subsidiary completes issuance of 1.5 billion yuan corporate bonds.

CHINARES PHARMA (03320) announced that its wholly-owned subsidiary CHINARES PHARMA Holdings Limited has issued the first tranche of 2026 corporate bonds in the People's Republic of China, according to the approval of the China Securities Regulatory Commission (CSRC Permit [2025] No. 1457). The approval allows CHINARES PHARMA Holdings to publicly issue corporate bonds in China to qualified investors, with a total principal amount not exceeding RMB 10 billion. The first tranche of RMB 1.5 billion 2026 corporate bonds has been issued with a term of 3 years and a coupon rate of 1.65%. The net proceeds will be used for productive expenditures, including repaying company debts, supplementing operational capital, project development and operational expenses, investments related to science and technology innovation, and other purposes in compliance with applicable laws and regulations.